Skip to Content
Current OncologyCurrent Oncology
  • Article
  • Open Access

1 May 2020

4 Pages

Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres

,
,
,
,
,
and
1
Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
2
Centre Hospitalier Régional de Trois-Rivières, Université de Montréal, Trois-Rivières, QC, Canada
3
The Ottawa Hospital, Ottawa, ON, Canada
4
Burnaby Hospital, Burnaby, BC, Canada

Abstract

Results of studies comparing subcutaneous (sc) with intravenous (iv) rituximab indicate that the two formulations are comparable in efficacy, but most patients and health care professionals prefer the sc route, commonly because of shorter chair time and reduced risk of infusion-related reactions. Recent Canadian data, including those from the scuba study reported here, support the results of earlier international studies showing a reduction in preparation and administration time with the sc formulation, lower cost of administration, and reduced drug wastage because of the fixed sc dosing. Given the significant time and cost savings of the sc formulation, that formulation is generally preferred over the iv formulation for the treatment of follicular lymphoma, diffuse large B cell lymphoma, and chronic lymphocytic leukemia.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.